- Investing Ideas
- U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt
U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt
Results
12
Stocks with a return on equity of over 30% and a debt to equity ratio below 1.
12 companies
Gilead Sciences
Market Cap: US$166.9b
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
GILD
US$134.43
7D
0.05%
1Y
22.1%
Illumina
Market Cap: US$24.7b
Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
ILMN
US$162.96
7D
12.8%
1Y
98.2%
Exelixis
Market Cap: US$12.7b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$50.48
7D
0.7%
1Y
17.3%
ACADIA Pharmaceuticals
Market Cap: US$3.7b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$21.66
7D
2.7%
1Y
0.4%
ADMA Biologics
Market Cap: US$1.8b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$7.98
7D
-3.2%
1Y
-59.8%
Innoviva
Market Cap: US$1.6b
Operates as a biopharmaceutical company in the United States and internationally.
INVA
US$21.42
7D
-4.6%
1Y
9.5%
Theravance Biopharma
Market Cap: US$828.2m
A biopharmaceutical company, develops and commercializes medicines in the United States.
TBPH
US$16.06
7D
-1.9%
1Y
75.3%
CorMedix
Market Cap: US$662.1m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$8.44
7D
5.8%
1Y
-30.5%
Abeona Therapeutics
Market Cap: US$329.4m
A commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
ABEO
US$5.78
7D
6.3%
1Y
-7.4%
Compugen
Market Cap: US$248.8m
A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
CGEN
US$2.63
7D
-6.1%
1Y
78.9%
Oramed Pharmaceuticals
Market Cap: US$162.5m
Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
ORMP
US$3.97
7D
-0.5%
1Y
69.7%
Vaxart
Market Cap: US$156.1m
A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform.
VXRT
US$0.65
7D
0.03%
1Y
48.9%